Osteoporosis clinical trials endpoints: Candidate variables and clinimetric properties

被引:0
作者
Cranney, A
Tugwell, P
Cummings, S
Sambrook, P
Adachi, J
Silman, AJ
Gillespie, WJ
Felson, DT
Shea, B
Wells, G
机构
[1] OTTAWA GEN HOSP,DEPT MED,OTTAWA,ON K1H 8L6,CANADA
[2] UNIV OTTAWA,DEPT MED,OTTAWA,ON,CANADA
[3] UNIV OTTAWA,CLIN EPIDEMIOL UNIT,OTTAWA,ON,CANADA
[4] ROYAL N SHORE HOSP,DEPT RHEUMATOL,SYDNEY,NSW,AUSTRALIA
[5] UNIV MANCHESTER,ARC EPIDEMIOL RES,MANCHESTER M13 9PL,LANCS,ENGLAND
[6] DEPT ORTHOPED SURG,EDINBURGH,MIDLOTHIAN,SCOTLAND
[7] BOSTON UNIV,ARTHRIT CTR,BOSTON,MA 02215
[8] UNIV CALIF SAN FRANCISCO,CHAIR INTERNAL MED,SAN FRANCISCO,CA 94143
[9] MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA
关键词
osteoporosis; outcomes; clinical trials;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We reviewed evidence on endpoints used in osteoporosis clinical trials to assist in the development of a set of endpoints to be included in all trials. A MEDLINE search was conducted using the Cochrane Collaboration strategy for each endpoint. Additional published literature was obtained from content experts. A proposed list of endpoints was developed after consultation with experts in the field. Each endpoint was evaluated with respect to validity, reproducibility, redundancy, and feasibility. We classified the endpoints into 2 major categories: clinical health status outcomes and intermediate endpoints, and for each endpoint we present current evidence from the literature as pertains to defined methodologic criteria. Multiple endpoints have been used in osteoporosis clinical trials, and an agreement on a core set of measures needs to be evidence based with an emphasis on validity, reproducibility, and feasibility and to satisfy clinical credibility.
引用
收藏
页码:1222 / 1229
页数:8
相关论文
共 74 条
[1]   The correlation of bone mineral density and biochemical markers to fracture risk [J].
Adachi, JD .
CALCIFIED TISSUE INTERNATIONAL, 1996, 59 :S16-S19
[2]  
BAUER DC, 1995, J BONE MINER RES, V10, P353
[3]  
Bellamy N, 1997, J RHEUMATOL, V24, P768
[4]  
Bellamy N, 1993, MUSCULOSKELETAL CLIN
[5]  
BLACK DM, 1995, J BONE MINER RES, V10, P890
[6]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[7]   VITAMIN-D(3) AND CALCIUM TO PREVENT HIP-FRACTURES IN ELDERLY WOMEN [J].
CHAPUY, MC ;
ARLOT, ME ;
DUBOEUF, F ;
BRUN, J ;
CROUZET, B ;
ARNAUD, S ;
DELMAS, PD ;
MEUNIER, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (23) :1637-1642
[8]   PREVENTION AND REHABILITATION OF OSTEOPOROSIS PROGRAM - EXERCISE AND OSTEOPOROSIS [J].
CHOW, R ;
HARRISON, J ;
DORNAN, J .
INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH, 1989, 12 (01) :49-56
[9]   QUALITY-OF-LIFE ISSUES IN WOMEN WITH VERTEBRAL FRACTURES DUE TO OSTEOPOROSIS [J].
COOK, DJ ;
GUYATT, GH ;
ADACHI, JD ;
CLIFTON, J ;
GRIFFITH, LE ;
EPSTEIN, RS ;
JUNIPER, EF .
ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :750-756
[10]   RISK-FACTORS FOR HIP FRACTURE IN WHITE WOMEN [J].
CUMMINGS, SR ;
NEVITT, MC ;
BROWNER, WS ;
STONE, K ;
FOX, KM ;
ENSRUD, KE ;
CAULEY, JC ;
BLACK, D ;
VOGT, TM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (12) :767-773